Thompson Investment Management Inc. Lowers Stake in GSK PLC Sponsored ADR $GSK

Thompson Investment Management Inc. reduced its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 39.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,420 shares of the pharmaceutical company’s stock after selling 916 shares during the period. Thompson Investment Management Inc.’s holdings in GSK were worth $55,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Dodge & Cox lifted its position in GSK by 14.9% during the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after acquiring an additional 10,210,921 shares during the period. Primecap Management Co. CA raised its holdings in GSK by 1.8% in the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock worth $995,929,000 after buying an additional 446,360 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in GSK by 2.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock worth $299,163,000 after buying an additional 155,392 shares during the last quarter. Royal Bank of Canada raised its holdings in GSK by 5.7% in the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock worth $293,692,000 after buying an additional 411,869 shares during the last quarter. Finally, Equity Investment Corp raised its holdings in GSK by 5.3% in the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company’s stock worth $161,708,000 after buying an additional 211,608 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Up 0.2%

GSK opened at $43.53 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The firm has a 50 day moving average price of $40.33 and a 200-day moving average price of $38.85. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $45.59. The stock has a market capitalization of $88.55 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 1.96 and a beta of 0.53.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same period in the previous year, the company earned $0.43 earnings per share. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were given a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.9%. The ex-dividend date was Friday, August 15th. GSK’s payout ratio is 78.24%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GSK. Weiss Ratings reaffirmed a “hold (c)” rating on shares of GSK in a report on Wednesday. Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.